FEATURED APPLICATION CONTENT

• Beyond The Bioreactor Scaling CGT Ancillary Materials With The EntoEngine™

  Growing demand for cell and gene therapies is increasing pressure on cytokine production. Explore interleukin manufacturing, quality, consistency, safety, scalability, and supply reliability.

• From Sequence To Scale In Seven Months

  Accelerate recombinant protein development from sequence to scale while maintaining stable expression, manufacturing efficiency, and critical quality attributes.

• Manufacturing Glycosylated Erythropoietin Without 𝛼1,3-Fucosylation

  See how expression hosts affect recombinant EPO glycosylation, bioactivity, and consistency, with reproducible N-glycan profiles and absence of α1,3-linked fucosylation.

• Characterization Of Fly-Derived Prolactin: Insights Into Glycosylation And Activity

  Explore how D. mel-derived human prolactin (hPRL) compares with hPRL expressed in E. coli and HEK293 cells through detailed physico-chemical and biological characterization.

• Overcoming The Obstacles Of Spray-Dried Dispersion Scale-Up

  SDD scale-up introduces scale-dependent risks that threaten bioavailability, stability, and manufacturability. This white paper details a model-based framework for managing those risks from early feasibility through commercial production.

• Chemoenzymatic N-glycan Conjugation Of Native mAbs Provides Homogeneous, Efficacious ADCs

  A chemoenzymatic two-stage protocol enables DAR2 ADCs from native, non-engineered mAbs via glycan remodeling at Asn-297 and copper-free click chemistry, with in vivo efficacy outperforming a comparable marketed ADC.

• Bringing Novel ADC Formats Into The Clinic: AOC Process Development

  Antibody-oligonucleotide conjugates introduce conjugation and purification challenges that standard ADC process development wasn't designed to solve. This white paper details practical approaches for each.

• Accelerating Cell Therapy Discovery With High-Throughput Electroporation

  Discover how high-throughput electroporation-based screening can compress your CAR-T optimization timeline while delivering reproducible, scale-ready results across multiple donor samples.

• Organ-On-A-Chip Technology Unlocks Patient-Derived Precision Medicine

  Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.

• How Isogenic Organ-Chips Are Transforming The Future Of Research

  Modeling the human brain requires more than simplified systems. New approaches that incorporate diverse cell types are improving how researchers study neurovascular function with greater precision.

• Shining A Light On Dark Data

  Centralizing data unlocks faster insights, reduces duplicated effort, and improves compliance. By overcoming silos and “dark data,” organizations can enable efficient search, reuse, and analysis.

• Filling Gaps In Drug Discovery Pipelines: From Candidate To Clinic

  See how existing partnerships with NIH allowed the chance to bring together government, academic, and industry resources through strategic initiatives that streamline processes and maximize benefits.